Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.

The cell cycle regulator, SKP2, is overexpressed in various cancers and plays a key role in p27 degradation, which is involved in tumor cell dedifferentiation. Little is known about the mechanisms leading to impaired SKP2 transcriptional control in tumor cells. We used neuroblastoma as a model to study SKP2 regulation because SKP2 transcript levels gradually increase with aggressiveness of neuroblastoma subtypes. The highest SKP2 levels are found in neuroblastomas with amplified MYCN. Accordingly, we found 5.5-fold (range, 2-9.5) higher SKP2 core promoter activity in MYCN-amplified cells. Higher SKP2 core promoter activity in MYCN-amplified cells is mediated through a defined region at the transcriptional start site. This region includes a specific E2F-binding site that makes SKP2 activation largely independent of mitogenic signals integrated through the SP1/ELK-1 site. We show by chromatin immunoprecipitation that SKP2 activation through the transcriptional start site in MYCN-amplified cells is associated with the low abundance of pRB-E2F1 complexes bound to the SKP2 promoter. Transcriptional control of SKP2 through this regulatory mechanism can be reestablished in MYCN-amplified cells by restoring pRB activity using selective small compound inhibitors of CDK4. In contrast, doxorubicin or nutlin-3 treatment-both leading to p53-p21 activation-or CDK2 inhibition had no effect on SKP2 regulation in MYCN-amplified cells. Together, this implies that deregulated MYCN protein levels in MYCN-amplified neuroblastoma cells activate SKP2 through CDK4 induction, abrogating repressive pRB-E2F1 complexes bound to the SKP2 promoter.

[1]  J. Pipas,et al.  E2F1-3 Switch from Activators in Progenitor Cells to Repressors in Differentiating Cells , 2009, Nature.

[2]  F. Westermann,et al.  Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. , 2009, Cancer letters.

[3]  Rainer König,et al.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas , 2008, Genome Biology.

[4]  F. Westermann,et al.  Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. , 2008, Carcinogenesis.

[5]  F. Westermann,et al.  Histone deacetylase inhibitor Helminthosporium carbonum (HC)‐toxin suppresses the malignant phenotype of neuroblastoma cells , 2007, International journal of cancer.

[6]  James M. Roberts,et al.  A Skp2 autoinduction loop and restriction point control , 2007, The Journal of cell biology.

[7]  J. Khan,et al.  High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status , 2007, Clinical Cancer Research.

[8]  Patrick Warnat,et al.  Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Appleman,et al.  CD28 Costimulation Mediates Transcription of SKP2 and CKS1, the Substrate Recognition Components of SCFSkp2 Ubiquitin Ligase That Leads p27kip1 to Degradation , 2006, Cell cycle.

[10]  C. Wang,et al.  F-box protein Skp2: a novel transcriptional target of E2F , 2006, Oncogene.

[11]  B. Gabrielli,et al.  Inhibition of S/G2 Phase CDK4 Reduces Mitotic Fidelity* , 2006, Journal of Biological Chemistry.

[12]  K. Nowak,et al.  BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas , 2006, Nucleic acids research.

[13]  Axel Benner,et al.  Reduced Expression of CAMTA1 Correlates with Adverse Outcome in Neuroblastoma Patients , 2006, Clinical Cancer Research.

[14]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[15]  D. Cobrinik.  Pocket proteins and cell cycle control , 2005, Oncogene.

[16]  Jiandong Chen,et al.  Activation of p27Kip1 Expression by E2F1 , 2005, Journal of Biological Chemistry.

[17]  Michele Pagano,et al.  An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. , 2004, Molecular cell.

[18]  W. Gerald,et al.  Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control , 2004, Nature.

[19]  A. Gartel,et al.  Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle , 2004, Oncogene.

[20]  W. Lutz,et al.  E2F and Sp1/Sp3 Synergize but Are Not Sufficient to Activate the MYCN Gene in Neuroblastomas* , 2004, Journal of Biological Chemistry.

[21]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[22]  Michele Pagano,et al.  When protein destruction runs amok, malignancy is on the loose. , 2003, Cancer cell.

[23]  M. Kitagawa,et al.  Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. , 2003, Cancer research.

[24]  F. Holstege,et al.  Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector , 2003, EMBO reports.

[25]  Michele Pagano,et al.  Deregulated degradation of the cdk inhibitor p27 and malignant transformation. , 2003, Seminars in cancer biology.

[26]  F. Westermann,et al.  Ataxin-2 promotes apoptosis of human neuroblastoma cells , 2003, Oncogene.

[27]  S. Elledge,et al.  Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex , 2002, Nature.

[28]  P. Fernandez,et al.  Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.

[29]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[30]  M. Kitagawa,et al.  The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2. , 1996, The EMBO journal.

[31]  M. Schwab,et al.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. , 1996, Oncogene.

[32]  J. Nevins,et al.  Regulation of the cyclin E gene by transcription factor E2F1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Pelletier,et al.  Absence of p53 gene mutations in primary neuroblastomas. , 1993, Cancer research.